Host STAT2/type I interferon axis controls tumor growth.

Host STAT2/type I interferon axis controls tumor growth.
复制标题

DOI:
10.1002/ijc.29004
复制
发表时间:
2015-01-01
影响因子:
6.4
通讯作者:
Gamero, Ana M.
Gamero, Ana M.
中科院分区:
医学1区
文献类型:
--
作者:
Yue, Chanyu;Xu, Jun;Estioko, Marc Daryl Tan;Kotredes, Kevin P.;Lopez-Otalora, Yolanda;Hilliard, Brendan A.;Baker, Darren P.;Gallucci, Stefania;Gamero, Ana M.

文献摘要

参考文献

被引文献

相似文献

在体外,STAT2在I型干扰素的抗生长作用中的作用已经得到了很好的证明。然而,目前还没有证据表明干扰素激活的STAT2在体内具有肿瘤抑制功能,并参与了抗肿瘤免疫。在这里,我们展示了在同基因肿瘤移植模型中,STAT2减少了肿瘤的生长。与野生型(WT)小鼠相比,STAT2−/−小鼠形成了更大的肿瘤。干扰素-β治疗STAT2−/−小鼠未见肿瘤消退。基因表达分析显示,在STAT2−/−小鼠体内建立的肿瘤中,免疫调节基因的一小部分下调。此外,我们还发现STAT2STAT2−/−树突状细胞对T细胞的肿瘤抗原交叉提呈功能受损。由STAT2−/−树突状细胞激活的肿瘤抗原特异性CD8+T细胞过继转移到荷瘤的STAT2−/−小鼠体内,在干扰素-β干预下不能诱导肿瘤消退。我们观察到,干扰素-β治疗的荷瘤WT小鼠的引流淋巴结中的CD_4~+和CD_8~+T细胞数量在干扰素-β治疗的STAT2−/−小鼠中没有增加。因此,我们的研究为进一步评估接受I型干扰素免疫治疗的癌症患者的STAT2功能提供了证据。
The role of STAT2 in mediating the antigrowth effects of type I interferon (IFN) is well-documented in vitro. Yet evidence of IFN-activated STAT2 as having tumor suppressor function in vivo and participation in antitumor immunity is lacking. Here we show in a syngeneic tumor transplantation model that STAT2 reduces tumor growth. Stat2−/− mice formed larger tumors compared to wild type (WT) mice. IFN-β treatment of Stat2−/− mice did not cause tumor regression. Gene expression analysis revealed a small subset of immunomodulatory genes to be downregulated in tumors established in Stat2−/− mice. Additionally, we found tumor antigen cross-presentation by Stat2−/− dendritic cells to T cells to be impaired. Adoptive transfer of tumor antigen specific CD8+ T cells primed by Stat2−/− dendritic cells into tumor-bearing Stat2−/− mice did not induce tumor regression with IFN-β intervention. We observed that an increase in the number of CD4+ and CD8+ T cells in the draining lymph nodes of IFN-β-treated tumor-bearing WT mice was absent in IFN-β treated Stat2−/− mice. Thus our study provides evidence for further evaluation of STAT2 function in cancer patients receiving type I IFN based immunotherapy.
DOI: 10.1084/jem.20101159
发表时间: 2011-09-26
期刊: The Journal of experimental medicine
影响因子: --
作者:
Fuertes MB;Kacha AK;Kline J;Woo SR;Kranz DM;Murphy KM;Gajewski TF
通讯作者: Gajewski TF
DOI: 10.1158/0008-5472.can-10-2820
发表时间: 2011-04-01
期刊: Cancer research
影响因子: 11.2
作者:
Burnette BC;Liang H;Lee Y;Chlewicki L;Khodarev NN;Weichselbaum RR;Fu YX;Auh SL
通讯作者: Auh SL
DOI: 10.1038/sj.onc.1201677
发表时间: 1998-03-26
期刊: ONCOGENE
影响因子: 8
作者:
Lembo, M;Sacchi, C;Landolfo, S
通讯作者: Landolfo, S
DOI: 10.1158/1078-0432.ccr-11-0503
发表时间: 2011-08-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Klebanoff CA;Gattinoni L;Palmer DC;Muranski P;Ji Y;Hinrichs CS;Borman ZA;Kerkar SP;Scott CD;Finkelstein SE;Rosenberg SA;Restifo NP
通讯作者: Restifo NP
DOI: 10.1038/ni1213
发表时间: 2005-07-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Dunn, GP;Bruce, AT;Schreiber, RD
通讯作者: Schreiber, RD